跳至主要内容
临床试验/NCT03587064
NCT03587064
招募中
不适用

Non-inferiority Randomized Clinical Investigation of CRT-DX Versus CRT-D Systems

Associazione Portatori Dispositivi Impiantabili Cardiaci24 个研究点 分布在 1 个国家目标入组 640 人开始时间: 2018年10月22日最近更新:

概览

阶段
不适用
状态
招募中
发起方
Associazione Portatori Dispositivi Impiantabili Cardiaci
入组人数
640
试验地点
24
主要终点
Combined endpoint of Mortality, hospitalization due to cardiac causes and lead-related complications

概览

简要总结

The principal objective is to test non-inferiority of the CRT-DX system as compared to a conventional CRT-D system, in terms of the combined endpoint of mortality, hospitalizations due cardiovascular causes, any complication leading to loss of lead functionality, in the subset of patients without evidence of sinus dysfunction on optimal therapy.

详细描述

Resting heart rate is strongly associated with incident worsening Heart Failure (HF) and mortality. Current devices for cardiac resynchronization (CRT-D) normally provide atrio-ventricular (AV) sequential pacing modes during resynchronization, but the best pacing programming strategy is not clear.

On the one hand a basic rate of 50 to 70 bpm (optionally with some rate-responsive function) could be considered for therapy up-titration, specifically betablockers; on the other hand, increasing pacing rates may partially reduce benefits from resynchronization, reducing filling time and contractility reservoir.

The Pegasus investigation is the only large randomized investigation comparing DDD with 70 bpm basic rate to DDD(R) @40 bpm. Results showed no difference in investigation endpoints, including mortality and HF-hospitalization.

These results may support the use of a device implementing both a CRT function and a right ventricular single-lead with and an atrial sensing dipole (CRT-DX system). This system can track ventricular pacing and resynchronization following atrial sensing, even if it cannot provide atrial pacing support. It should be assessed whether such limitation is counterbalanced by the advantages related to the reduced number of necessary leads, with simplified implantation and less complications.

The objective of the investigation is to assess whether atrial pacing support is really necessary in the subset of patients with indication to CRT-D and no evidence of sinus dysfunction on optimal therapy. The investigation will test the hypothesis that a CRT-DX system is not inferior to a conventional CRT-D system in this class of subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female patients ≥ 18 years old
  • Patients willing to participate in the investigation and signing the Patient Informed Consent (PIC) Form;
  • Indication to CRT-D implant according to current ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
  • Sinus rhythm at time of implant;
  • Optimized medical therapy according to current ESC Guidelines
  • Rest heart rate (HR) \>45 bpm at baseline ECG, with betablocker therapy at optimal medical dosage; or, if rest HR\<45 bpm: maximum heart rate at the 6- minute walking test \>85 bpm.

排除标准

  • Any indication to atrial pacing according to current guidelines;
  • Both: resting heart rate \<45 bpm at baseline ECG, with betablocker therapy at optimal medical dosage and maximum heart rate at the 6-minute walking test \<85 bpm;
  • NYHA Class IV;
  • Permanent Atrial Fibrillation
  • Replacement of/upgrading from previously implanted pacing system;
  • Dialysis patients;
  • Pregnant or breast-feeding women.

结局指标

主要结局

Combined endpoint of Mortality, hospitalization due to cardiac causes and lead-related complications

时间窗: 1 year

It includes number of patients who experienced death, hospitalization due to cardiac causes, or any lead-related complication leading to loss of functionality (including lead dislodgement, conduction or insulation failure, loss of sensing or capture that couldn't resolved by reprogramming)

次要结局

  • Rate of inappropriate therapy of the device(1 year)
  • Atrial pacing percentage(1 year)
  • Incidence of events due to short-long-short sequence(1 year)
  • Implant failure(1 year)
  • Far field oversensing incidence(1 year)
  • Device detected AT(1 year)
  • Exercise test(1 year)
  • Procedure times(1 year)
  • Atrial sensing amplitude measured by device(1 year)
  • Incidence of appropriate Ventricular therapy(1 year)
  • Rate of implant revisions(1 year)

研究者

发起方
Associazione Portatori Dispositivi Impiantabili Cardiaci
申办方类型
Other
责任方
Sponsor

研究点 (24)

Loading locations...

相似试验